Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

NCT04567303 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Zifibancimig
DRUG: Ranibizumab
DEVICE: Port Delivery Platform

Sponsor

Hoffmann-La Roche